Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenapyr (CD19 CAR-T) + ASCT + obetinib + sintilimab in primary/relapsed refractory CNS diffuse large B-cell lymphoma
ChiCTR2500109605Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of regorafenib, obetinib and sintilimab in Diffuse Large B-Cell Primary Central Nervous System Lymphoma and diffuse large B-cell lymphoma (DLBCL), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Overall survival. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
regorafenibobetinibsintilimab
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2500109605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109605.